Verici Dx Plc · LSE:VRCI
Verici Dx — H1 2023 Earnings Presentation
16 slides from Verici Dx's earnings presentation, October 2023
Slide 1: Interim Results to 30 June 2023
Interim Results to 30 June 2023 October 2023 Transforming kidney transplant outcomes
Slide 2: Disclaimer
DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA (THE "U.S.") (EXCEPT TO CERTAIN INVITED QIBS AND AIS (AS DEFINED BELOW), CANADA, AUSTRALIA, JAPAN OR ANY JURISD
Slide 3: Clear market opportunity with compelling company positioning
Clear market opportunity with compelling company positioning Significant Unmet - Unacceptably high rate of transplant rejection (37-50%) with inadequate standard of care Need and Large - Large addressable market opportunity worth over $5bn and growing Market - RNA signature-based transplant technolo
Slide 4: Addressing a critical need for personalized diagnostic information
Addressing a critical need for personalized diagnostic information What is the risk of Is the graft being rejected rejection? or damaged? Current practice: Current practice: Standard of Care Broad Clinical Factors/Score • Misses 30% of all cases • Too general and Therapeutic Dilemma largely ignored
Slide 5: Through three foundational tests, enhanced end-to-end transplant testing for improved outcomes
Through three foundational tests, enhanced end-to-end transplant testing for improved outcomes Pre-Transplant Prognostic Patients now can Post-Transplant Prognostic mRNA 10 gene Signature be prescribed mRNA 17 gene Signature treatment at an Advantages: Advantages: • Provides risk score for early acu
Slide 6: Excellent progress in H1 and since creates strong platform for future growth
Excellent progress in H1 and since creates strong platform for future growth • Two clinically validated products: − Tutivia ™: Positive clinician feedback following its commercial launch at the start of the year • Peer-reviewed publication imminent − Clarava™: On track for initial US commercial use
Slide 7: Maintaining momentum despite some operational headwinds
Maintaining momentum despite some operational headwinds • Initial transplant centre adoption − Slower than anticipated § CMS “clarifications” caused short-term confusion. This appears to be resolving in Q3 § Logistical issues around sample collection process now resolved with a new approach in opera
Slide 8: Positive operational and commercial outlook
Positive operational and commercial outlook • Tutivia™: Increasing adoption and tests ordered − Doubled the number of centers in the early adoption programme through Q3 − Excellent clinical feedback – follow us on Social Media (e.g. LinkedIn, X etc.) for clinician video interviews − Medicare and pri
Slide 9: Underpinned by an unparalleled data set for leading competitive advantage
Underpinned by an unparalleled data set for leading competitive advantage Specimens on blood, urine and tissue as well as Next Patient information samples and CLINICAL Generation Sequencing (NGS) BIOMARKERS therapeutic dosing information enables data capture on the DATA collected on a longitudinal b
Slide 10: Cash Flow Statement
Cash Flow Statement Six months to 30 June 2023 Comments Unaudited $’000 • Operating outflow in H1 2022 of $5.0m. Net outflow from operating activities (4,766) • Investing flows: capex ($23k) and spend Investing activities (106) on patents ($83k). Financing activities 28 • Financing flows: interest (
Slide 11: Income Statement
Income Statement Six months to 30 June 2023 Comments Unaudited $’000 • Revenues of $19k Gross margin 16 • Largest items of expenditure: Administrative expenses (4,825) - Wages: $1.8m with average 14 members of staff – prior period $1.3m with Depreciation and amortisation (472) average 10 members of
Slide 12: Balance Sheet
Balance Sheet As of 30 June 2023 Comments Unaudited $’000 • Tangibles: includes $823k spent over the Tangible assets 1,641 period on CLIA lab Intangible assets 2,037 • Intangible: $1.5m cost of original license from Renalytix and additional spend on Trade and other receivables 426 patents Cash at ba
Slide 13: Follow us
Follow us LinkedIn: linkedin.com/company/verici-dx Twitter: @VericiDx Website: vericidx.com 13
Slide 14: Appendix
Appendix • Board • Scientific Advisory Board 14
Slide 15: Experienced Leadership for developing and commercializing kidney transplants assays
Experienced Leadership for developing and commercializing kidney transplants assays Sir Ian Carruthers Julian Baines Senior Independent Non-executive Chairman Non-executive Director EKF Diagnostics, BBI Chancellor UWE, Snr Director NHS Lorenzo Gallon Erik Lium Independent Non-executive Non-executive
Slide 16: Multinational Science Advisory Board of Key Opinion Leaders
Multinational Science Advisory Board of Key Opinion Leaders Lorenzo Gallon, MD (Chair) • Five (5) past presidents of major Tony Dorling, MD international Transplant organizations Richard Formica, MD (AST, TTS, ASTS) Roslyn Mannon, MD • Current President of American Peter Nickerson, MD Society of Tra